Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice

Nephrology Dialysis Transplantation

Volumn 28, Issue 4, 2013, Pages 879-889

  Van Angelen, Annelies A ^a   Glaudemans, Bob ^a   Van Der Kemp, Annemiete W C M ^a   Hoenderop, Joost G J ^a   Bindels, René J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cisplatin; DCT; hypomagnesaemia; mouse; nephrotoxicity

Indexed keywords

AQUAPORIN 1; AQUAPORIN 2; CALCIUM; CISPLATIN; CLAUDIN 16; CREATININE; MAGNESIUM; MESSENGER RNA; PARVALBUMIN; POTASSIUM; SODIUM; SODIUM CHLORIDE; SODIUM CHLORIDE COTRANSPORTER; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DOWN REGULATION; ELECTROLYTE URINE LEVEL; FEMALE; GENE EXPRESSION; GENETIC MARKER; HYPOMAGNESEMIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY DISTAL TUBULE; KIDNEY TUBULE; MAGNESIUM BLOOD LEVEL; MOUSE; NEPHROTOXICITY; NONHUMAN; POLYURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SODIUM BLOOD LEVEL; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AQUAPORIN 2; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CISPLATIN; ELECTROLYTES; FEMALE; GLOMERULAR FILTRATION RATE; IMMUNOENZYME TECHNIQUES; KIDNEY DISEASES; KIDNEY TUBULES, DISTAL; MAGNESIUM DEFICIENCY; MICE; MICE, INBRED C57BL; PARVALBUMINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DRUG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYMPORTERS; TRPM CATION CHANNELS;

EID: 84875972623     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs499     Document Type: Article

References (63)

1. Rosenberg B, VanCamp L, Trosko JE et al. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385-386
2. Roberts JJ, Pascoe JM. Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds. Nature 1972; 235: 282-284
3. Rosenberg B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 1973; 60: 399-406
4. Yao X, Panichpisal K, Kurtzman N et al. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115-124 (Pubitemid 47262919)
5. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464 (Pubitemid 37176691)
6. Dobyan DC, Levi J, Jacobs C et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980; 213: 551-556 (Pubitemid 10085160)
7. Mavichak V, Wong NL, Quamme GA et al. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 1985; 28: 914-921 (Pubitemid 16148393)
8. Daugaard G, Abildgaard U, Larsen S et al. Functional and histopathological changes in dog kidneys after administration of cisplatin. Ren Physiol 1987; 10: 54-64 (Pubitemid 18070854)
9. Gonzales-Vitale JC, Hayes DM, Cvitkovic E et al. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39: 1362-1371 (Pubitemid 8108286)
10. Magil AB, Mavichak V, Wong NL et al. Long-term morphological and biochemical observations in cisplatin-induced hypomagnesemia in rats. Nephron 1986; 43: 223-230 (Pubitemid 16084324)
11. Takashi M, Zhu Y, Miyake K et al. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy. Urol Int 1996; 56: 174-179 (Pubitemid 26122046)
12. Orfila C, Bompart G, Lepert JC et al. Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats. Histochem J 1993; 25: 772-777 (Pubitemid 23312021)
13. Bompart G, Orfila C, Girolami JP. Distal nephrotoxicity of cisplatin demonstrated by urinary kallikrein excretion and morphological study in rats. Toxicology 1991; 69: 121-132
14. Lam M, Adelstein DJ. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 1986; 8: 164-169 (Pubitemid 17217090)
15. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90: 929-931 (Pubitemid 9244593)
16. Ariceta G, Rodriguez-Soriano J, Vallo A et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 1997; 28: 35-40 (Pubitemid 27023774)
17. Jones DP, Chesney RW. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin. Curr Opin Pediatr 1995; 7: 208-213
18. Panichpisal K, Angulo-Pernett F, Selhi S et al. Gitelman-like syndrome after cisplatin therapy: a case report and literature review. BMC Nephrol 2006; 7: 10
19. Vassal G, Rubie H, Kalifa C et al. Hyponatremia and renal sodium wasting in patients receiving cisplatinum. Pediatr Hematol Oncol 1987; 4: 337-344 (Pubitemid 18040393)
20. Dai LJ, Ritchie G, Kerstan D et al. Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001; 81: 51-84 (Pubitemid 32096173)
21. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58 (Pubitemid 29178536)
22. Mavichak V, Coppin CM, Wong NL et al. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. Clin Sci (Lond) 1988; 75: 203-207
23. Ludwig T, Riethmuller C, Gekle M et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004; 66: 196-202 (Pubitemid 38870095)
24. Litterst CL, Gram TE, Dedrick RL et al. Distribution and disposition of platinum following intravenous administration of cisdiamminedichloroplatinum( II) (NSC 119875) to dogs. Cancer Res 1976; 36(7 Pt 1): 2340-2344
25. Hall MD, Okabe M, Shen DW et al. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008; 48: 495-535 (Pubitemid 351738162)
26. Glaudemans B, Knoers NV, Hoenderop JG et al. New molecular players facilitating Mg(2+) reabsorption in the distal convoluted tubule. Kidney Int 2010; 77: 17-22
27. Hoenderop JG, Muller D, Van Der Kemp AW et al. Calcitriol controls the epithelial calcium channel in kidney. J Am Soc Nephrol 2001; 12: 1342-1349 (Pubitemid 32666317)
28. Jennings ML. Monoclonal antibody against red blood cell CHIP28 protein. J Gen Physiol 1992; 100(21A): 21A
29. Nijenhuis T, Hoenderop JG, Loffing J et al. Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in kidney. Kidney Int 2003; 64: 555-564 (Pubitemid 36871926)
30. Ichimura T, Hung CC, Yang SA et al. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol 2004; 286: F552-F563 (Pubitemid 38233650)
31. Hou J, Renigunta A, Konrad M et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 2008; 118: 619-628 (Pubitemid 351206551)
32. Amemiya M, Loffing J, Lotscher M et al. Expression of NHE-3 in the apical membrane of rat renal proximal tubule and thick ascending limb. Kidney Int 1995; 48: 1206-1215
33. Nishinaga H, Komatsu R, Doi M et al. Circadian expression of the Na+/H+ exchanger NHE3 in the mouse renal medulla. Biomed Res (Tokyo, Japan) 2009; 30: 87-93
34. Andrews PA, Velury S, Mann SC et al. cis-Diamminedichloroplatinum( II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 68-73 (Pubitemid 18030332)
35. Mann SC, Andrews PA, Howell SB. Modulation of cis- diamminedichloroplatinum( II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991; 48: 866-872
36. Ciarimboli G, Ludwig T, Lang D et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter Am J Pathol 2005; 167: 1477-1484 (Pubitemid 41713303)
37. Ishida S, Lee J, Thiele DJ et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298-14302 (Pubitemid 35257666)
38. Schlingmann KP, Weber S, Peters M et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31: 166-170
39. Voets T, Nilius B, Hoefs S et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004; 279: 19-25 (Pubitemid 38044794)
40. Lajer H, Kristensen M, Hansen HH et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005; 56: 535-542 (Pubitemid 41549156)
41. Willox JC, McAllister EJ, Sangster G et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin: a randomised trial. Br J Cancer 1986; 54: 19-23 (Pubitemid 16093180)
42. Reilly RF, Ellison DH. Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. Physiol Rev 2000; 80: 277-313 (Pubitemid 30060566)
43. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572 (Pubitemid 37430158)
44. Zhang J, Goering PL, Espandiari P et al. Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. Toxicol Pathol 2009; 37: 629-643
45. Sabolic I, Skarica M, Gorboulev V et al. Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences. Am J Physiol 2006; 290: F913-F926 (Pubitemid 43724954)
46. Maunsbach AB, Marples D, Chin E et al. Aquaporin-1 water channel expression in human kidney. J Am Soc Nephrol 1997; 8: 1-14 (Pubitemid 27496510)
47. Murer H, Hernando N, Forster I et al. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80: 1373-1409
48. Ecelbarger CA, Sands JM, Doran JJ et al. Expression of salt and urea transporters in rat kidney during cisplatin-induced polyuria. Kidney Int 2001; 60: 2274-2282 (Pubitemid 33070469)
49. Kishore BK, Krane CM, Di Iulio D et al. Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int 2000; 58: 701-711 (Pubitemid 30620019)
50. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Phys 1966; 79: 221-235
51. Simon DB, Lifton RP. The molecular basis of inherited hypokalemic alkalosis: Bartter's and Gitelman's syndromes. Am J Physiol 1996; 271(5 Pt 2): F961-F966
52. Barker NW, Carey B, Brough W. Effect of chlorothiazide on patients with edema of the lower extremities of local origin. Minn Med 1959; 42: 227-230
53. Poutsiaka JW, Madissoo H, Millstein LG et al. Effects of benzydroflumethiazide (Naturetin) on the renal excretion of calcium and magnesium by dogs. Toxicol Appl Pharmacol 1961; 3: 455-458
54. Greger R. Why do loop diuretics cause hypokalaemia? Nephrol Dial Transplant 1997; 12: 1799-1801 (Pubitemid 27379442)
55. Nijenhuis T, Vallon V, van der Kemp AW et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005; 115: 1651-1658 (Pubitemid 40814674)
56. Yang Z, Schumaker LM, Egorin MJ et al. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 2006; 12: 5817-5825 (Pubitemid 44629614)
57. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev 2005; 4: 307-320 (Pubitemid 41130944)
58. Linss W, Geyer G. The electron microscopic structure of the kidney tubule in rana esculenta. Anat Anz 1964; 115: 281-296
59. Qian W, Nishikawa M, Haque AM et al. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol 2005; 289: C1466-C1475 (Pubitemid 41636351)
60. Kuo YM, Gybina AA, Pyatskowit JW et al. Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J Nutr 2006; 136: 21-26 (Pubitemid 43156479)
61. Beretta GL, Gatti L, Tinelli S et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and-resistant cells. Biochem Pharmacol 2004; 68: 283-291 (Pubitemid 38757697)
62. Filipski KK, Mathijssen RH, Mikkelsen TS et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86: 396-402
63. Pabla N, Dong G, Jiang M et al. Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 2011; 121: 2709-2722